Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 1:14:1060504.
doi: 10.3389/fgene.2023.1060504. eCollection 2023.

Clinical usefulness of NGS multi-gene panel testing in hereditary cancer analysis

Federico Anaclerio  1 , Lucrezia Pilenzi  1 , Anastasia Dell'Elice  1 , Rossella Ferrante  1 , Simona Grossi  2 , Luca Maria Ferlito  2 , Camilla Marinelli  2 , Simona Gildetti  2 , Giuseppe Calabrese  3 , Liborio Stuppia  1 , Ivana Antonucci  1
Affiliations

Clinical usefulness of NGS multi-gene panel testing in hereditary cancer analysis

Federico Anaclerio et al. Front Genet. .

Abstract

Introduction: A considerable number of families with pedigrees suggestive of a Mendelian form of Breast Cancer (BC), Ovarian Cancer (OC), or Pancreatic Cancer (PC) do not show detectable BRCA1/2 mutations after genetic testing. The use of multi-gene hereditary cancer panels increases the possibility to identify individuals with cancer predisposing gene variants. Our study was aimed to evaluate the increase in the detection rate of pathogenic mutations in BC, OC, and PC patients when using a multi-gene panel. Methods: 546 patients affected by BC (423), PC (64), or OC (59) entered the study from January 2020 to December 2021. For BC patients, inclusion criteria were i) positive cancer family background, ii) early onset, and iii) triple negative BC. PC patients were enrolled when affected by metastatic cancer, while OC patients were all submitted to genetic testing without selection. The patients were tested using a Next-Generation Sequencing (NGS) panel containing 25 genes in addition to BRCA1/2. Results: Forty-four out of 546 patients (8%) carried germline pathogenic/likely pathogenic variants (PV/LPV) on BRCA1/2 genes, and 46 (8%) presented PV or LPV in other susceptibility genes. Discussion: Our findings demonstrate the utility of expanded panel testing in patients with suspected hereditary cancer syndromes, since this approach increased the mutation detection rate of 15% in PC, 8% in BC and 5% in OC cases. In absence of multi-gene panel analysis, a considerable percentage of mutations would have been lost.

Keywords: BRCA; NGS; breast cancer; cancer predisposition gene; hereditary cancer; multi-gene panel testing; ovarian cancer; pancreatic cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
All cases analyzed with multi-gene panel.
FIGURE 2
FIGURE 2
(A) All genes with PV/LPV in Breast Cancer cases; (B) All genes with PV/LPV in Pancreatic Cancer cases.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Antonucci I., Provenzano M., Sorino L., Balsamo M., Battista P., Euhus D., et al. (2017a). Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: A retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer. J. Hum. Genet. 62 (3), 379–387. 10.1038/jhg.2016.138 - DOI - PubMed
    1. Antonucci I., Provenzano M., Sorino L., Rodrigues M., Palka G., Stuppia L. (2017b). A new case of “de Novo” BRCA1 mutation in a patient with early-onset breast cancer. Clin. Case Rep. 5 (3), 238–240. 10.1002/ccr3.718 - DOI - PMC - PubMed
    1. Babore A., Bramanti S. M., Lombardi L., Stuppia L., Trumello C., Antonucci I., et al. (2019). The role of depression and emotion regulation on parenting stress in a sample of mothers with cancer. Support Care Cancer 27 (4), 1271–1277. 10.1007/s00520-018-4611-5 - DOI - PubMed
    1. Bono M., Fanale D., Incorvaia L., Cancelliere D., Fiorino A., Calò V., et al. (2021). Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: Looking over the hedge. ESMO Open 6 (4), 100235. 10.1016/j.esmoop.2021.100235 - DOI - PMC - PubMed
    1. Breast Cancer Association Consortium, Dorling L., Carvalho S., Allen J., González-Neira A., Craig L., Wahlström C., et al. (2021). Breast cancer risk genes - association analysis in more than 113,000 women. N. Engl. J. Med. 384 (5), 428–439. 10.1056/NEJMoa1913948 - DOI - PMC - PubMed